LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• LifeMD has a “Moderate Buy” consensus rating from 10 analysts: eight recommend buying, one rates it a hold and one recommends selling. The average 12-month price target is $7.57.
• Several firms remain bullish, including B. Riley and HC Wainwright, which issued buy ratings with $8 and $9 targets, respectively; however, Wall Street Zen downgraded the stock to sell.
• LifeMD shares opened at $2.74, near their 52-week low of $2.56, while the company’s latest quarterly results missed expectations on both earnings and revenue. Institutional investors own 35.52% of the stock.

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have earned an average rating of "Moderate Buy" from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.57.

Several research firms have recently weighed in on LFMD. Lake Street Capital set a $5.00 price target on LifeMD in a research note on Thursday, August 6th. B. Riley Financial began coverage on LifeMD in a report on Friday, September 11th. They issued a "buy" rating and a $8.00 price objective for the company. Wall Street Zen lowered LifeMD from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of LifeMD in a report on Thursday, September 17th. Finally, Zacks Research upgraded shares of LifeMD from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th.

Hedge Funds Weigh In On LifeMD

Institutional investors and hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new stake in shares of LifeMD in the second quarter worth $25,000. R Squared Ltd bought a new position in shares of LifeMD in the 1st quarter worth approximately $41,000. Corient Private Wealth LP purchased a new position in shares of LifeMD in the second quarter worth approximately $63,000. AXQ Capital LP bought a new stake in LifeMD during the fourth quarter valued at approximately $67,000. Finally, Quantbot Technologies LP bought a new stake in LifeMD during the second quarter valued at approximately $89,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Stock Performance

Shares of NASDAQ LFMD opened at $2.74 on Friday. The firm's 50 day moving average price is $3.27 and its 200-day moving average price is $3.97. The company has a market cap of $132.07 million, a PE ratio of -54.79 and a beta of 1.99. LifeMD has a 52-week low of $2.56 and a 52-week high of $7.32.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. On average, analysts forecast that LifeMD will post -0.48 earnings per share for the current fiscal year.

About LifeMD

LifeMD, Inc NASDAQ: LFMD is a U.S.-based telehealth company that provides virtual healthcare services through its digital platform. The company connects patients with licensed healthcare professionals through online consultations, enabling access to medical care, prescriptions, ongoing treatment and care-management services without requiring an in-person visit.

LifeMD offers services across several areas, including virtual primary care, men's and women's health, dermatology, mental health and weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.